Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance
Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …
Engineering immune-evasive allogeneic cellular immunotherapies
Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to
their potential cost-effectiveness, scalability and on-demand availability. However, immune …
their potential cost-effectiveness, scalability and on-demand availability. However, immune …
Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells
CR Maldini, AC Messana, PB Bendet, AJ Camblin… - Molecular Therapy, 2024 - cell.com
Chimeric antigen receptor (CAR) T cells from allogeneic donors promise" off-the-shelf"
availability by overcoming challenges associated with autologous cell manufacturing …
availability by overcoming challenges associated with autologous cell manufacturing …
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
N Tsuneyoshi, T Hosoya, Y Takeno, K Saitoh… - Stem Cell Research & …, 2024 - Springer
Background The human induced pluripotent stem cells (hiPSCs) can generate all the cells
composing the human body, theoretically. Therefore, hiPSCs are thought to be a candidate …
composing the human body, theoretically. Therefore, hiPSCs are thought to be a candidate …